What Impact is the Medicare Drug Price Negotiation Program Having on Pharmacies?

For decades, Medicare was legally prohibited from negotiating prescription drug prices directly with manufacturers. That changed with the Inflation Reduction Act of 2022, which established the Medicare Drug Price Negotiation Program (MDPNP) and gave the Centers for Medicare and Medicaid Services (CMS) the authority to negotiate prices for a select number of high-cost drugs covered under Medicare Part D and, from 2028 onward, Medicare Part B.

The first ten negotiated drugs took effect on January 1, 2026, representing discounts ranging from 38% to 79% off previous prices, according to OpenMedicare, across drugs that accounted for $56.2 billion in Medicare Part D spending, roughly 20% of all Part D drug costs. CMS projects first-year savings of approximately $6 billion for the program and $1.5 billion in out-of-pocket savings for the 8.8 million Part D enrollees who use these drugs.

For Medicare beneficiaries, the headlines are positive. For pharmacies, the picture is considerably more complicated. This post explains what the MDPNP actually means for pharmacy operations in 2026, what the financial risks look like in practice and what pharmacy owners can do to navigate the changes ahead.

What is the Medicare Drug Price Negotiation Program?

The MDPNP, established under the Inflation Reduction Act, authorizes the Secretary of Health and Human Services to negotiate prices for certain single-source drugs and biological products under Medicare Part D and Part B. To qualify for selection, a small-molecule drug must have had FDA approval for at least seven years and a biological product must have been FDA-licensed for at least eleven years. The negotiated prices are subject to a ceiling known as the Maximum Fair Price (MFP).

Before the IRA took effect, Medicare was prohibited from negotiating prices directly with drug companies. When the Part D program was established in 2003, it included a provision called the noninterference clause, which prohibited CMS from interfering with negotiations between Part D plan sponsors, manufacturers and pharmacies, as explained by the Commonwealth Fund. The MDPNP fundamentally changed that framework.

With 15 drugs added in 2027, 15 more in 2028 and 20 per year after that, the negotiation program will eventually cover hundreds of the most expensive drugs in Medicare. The Congressional Budget Office projects cumulative savings of $98.5 billion over ten years. The first ten drugs include widely dispensed medications for conditions including diabetes, heart failure, blood clots and Crohn's disease, covering patient populations that pharmacies across the country serve every day.

How the MDPNP works at the pharmacy level

Understanding the operational mechanics of the MDPNP is essential for pharmacy owners trying to assess its impact on their business. The way the Maximum Fair Price reaches the patient at the pharmacy counter is more complicated than it might appear from the headline figures.

Under the program, manufacturers are responsible for ensuring that the MFP is available to dispensing entities, either by selling the drug to the pharmacy at the MFP directly or by providing a retrospective MFP refund after the pharmacy has already dispensed the drug at a higher price. USC Schaeffer research notes that pharmacies remain concerned they are being put in the middle of the refund-implementation process in ways that will result in significant economic hardship, especially as the number of negotiated drugs grows.

The retrospective refund model is where the operational problem sits. Rather than receiving the negotiated price upfront at the point of dispensing, pharmacies in many cases dispense the drug at the existing price and then wait for a manufacturer refund to bridge the difference. That waiting period creates a cash flow gap that can compound significantly across a high-volume Medicare patient population.

The financial impact: What the data shows

A January 2025 analysis by 3 Axis Advisors, commissioned by the NCPA, found that the MDPNP could result in a weekly cash flow shortfall of $10,838.25 for the average pharmacy compared to prior operations, driven primarily by the delay between dispensing and receiving manufacturer refund payments.

The NCPA concluded that the MDPNP exposes pharmacies to significant financial risk, potentially disrupting seniors' access to essential medications and warned that implementation represents a fundamental shift in pharmacy operations and reimbursement practices for many of Medicare's most widely used brand medicines.

The stocking decision data makes the scale of pharmacy concern concrete. The same NCPA member survey found that 93.2% of pharmacies are either considering not stocking or have already chosen not to stock one or more of the first ten negotiated drugs. As STAT News reported, if pharmacies refuse to stock negotiated drugs, older adults will be left scrambling to obtain critical medications, with consequences felt most acutely in rural areas and pharmacy deserts.

The reimbursement concern: Will PBM rates adjust?

One of the most pressing questions for pharmacy owners is whether Part D plan reimbursement rates will adjust to reflect the new Maximum Fair Prices or whether plans will continue to set their own reimbursement terms independently of the MFP.

According to USC Schaeffer, pharmacies worry that Part D plans will continue to offer extremely aggressive reimbursement rates for negotiated drugs even after the MFP takes effect. If that concern proves well-founded, pharmacies could find themselves reimbursed below the MFP, waiting for a manufacturer refund to bridge the gap and carrying the cash flow risk in the meantime. Pharmacies have asked CMS to require Part D plans to pay reimbursements that reflect the MFP rather than continuing to set rates independently, though no requirement to that effect has yet been finalized.

What comes next: The expanding program

The ten drugs whose prices took effect in January 2026 are only the beginning. According to eMedicare, the 15 drugs selected for the 2027 negotiation round include medications for cancer, autoimmune disorders, blood disorders and cardiovascular disease, with final prices to be announced by August 2026.

The 2027 round also expands negotiation beyond the pharmacy counter for the first time to include Part B drugs, which tend to be the most expensive biologics administered in physician offices and infusion settings. For pharmacy owners, the practical implication is that the MDPNP is not a one-time operational adjustment. It is an ongoing and expanding program that will require active monitoring, financial planning and operational adaptation on a rolling basis for years ahead.

What pharmacy owners can do now

Identify which of the first ten drugs your pharmacy dispenses and at what volume

The financial impact of the MDPNP on any individual pharmacy is directly proportional to the volume of negotiated drugs it dispenses to Medicare Part D patients. Pharmacies with high volumes of the first ten negotiated drugs face significantly greater cash flow exposure than those for whom these drugs represent a small share of dispensing.

Monitor Part D plan reimbursement rates for negotiated drugs closely

The gap between what your Part D plan reimburses and what the MFP should be is the critical financial variable to track. If reimbursement rates are not adjusting to reflect the MFP, that gap needs to be understood and managed as a known cost of operation, not discovered retrospectively.

Stay current on CMS guidance and the Medicare Transaction Facilitator

CMS created the Medicare Transaction Facilitator (MTF) to manage the flow of MFP refunds between manufacturers and pharmacies. The operational details of how the MTF functions and how quickly refunds flow through it will significantly affect the cash flow impact on individual pharmacies. Staying current on CMS updates and NCPA guidance as the program matures is essential.

Maintain clean, retrievable dispensing and reimbursement records

The MDPNP introduces new complexity into pharmacy billing records, with multiple layers of pricing, refunds and reimbursement adjustments creating a documentation environment that is more audit-sensitive than a standard Part D claim. RxMile's record keeping and audit support tools help pharmacies maintain the complete, retrievable documentation records this environment demands.

Engage with your pharmacy association

The NCPA and state pharmacy associations are actively engaged in advocating for pharmacy protections within the MDPNP framework. Staying connected to association guidance and participating in advocacy efforts is one of the most direct ways pharmacy owners can contribute to shaping the program's implementation.

A program that saves patients money while raising hard questions for pharmacies

The Medicare Drug Price Negotiation Program represents a genuine and significant benefit for the Medicare patients pharmacies serve. Lower out-of-pocket costs for high-cost drugs, particularly for seniors managing chronic conditions on fixed incomes, is a meaningful improvement in patient access and affordability.

The challenge for pharmacy owners is that the mechanics of how those savings reach patients create real operational and financial risks at the pharmacy level. Cash flow gaps, reimbursement uncertainty and the expanding scope of the program all require active management rather than a wait-and-see approach.

The pharmacies that navigate the MDPNP most successfully will be those that understand the financial mechanics clearly, monitor their exposure actively, maintain clean documentation records across all negotiated drug transactions and stay engaged with the advocacy and guidance resources available through their associations.

RxMile's prescription delivery software and compliance tools help pharmacies build the operational infrastructure to maintain patient care standards and documentation integrity through periods of policy change. Start your 30-day free trial today.